Dr. Reddy's Laboratories Limited (BOM: 500124)
India
· Delayed Price · Currency is INR | Market Cap | 1.11T |
| Revenue (ttm) | 288.51B |
| Net Income (ttm) | 55.58B |
| Shares Out | 166.59M |
| EPS (ttm) | 333.26 |
| PE Ratio | 19.96 |
| Forward PE | 18.99 |
| Dividend | 40.00 (0.60%) |
| Ex-Dividend Date | Jul 16, 2024 |
| Volume | 9,092 |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | 5,212.10 - 7,101.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2024 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI se... [Read more]
Financial Performance
In 2023, Dr. Reddy's Laboratories's revenue was 279.16 billion, an increase of 13.54% compared to the previous year's 245.88 billion. Earnings were 55.68 billion, an increase of 23.56%.
Financial StatementsNews
Dr. Reddy’s refutes Congress allegations over engagement with Dhaval Buch’s Agora Advisory
Dr. Reddy’s clarified that it engaged Agora Advisory for a limited period from October 2020 to April 2021, specifically for leadership coaching services provided by Mr. Dhaval Buch.
Dr. Reddy’s Laboratories receives USFDA EIR for Srikakulam API facility inspection
Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY, BSE: 500124, NYSE: RDY) has announced that it received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA)...
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again?
Dr. Reddy's Labs sees its Relative Strength Rating enter the 80-plus level.
Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry com...
Dr. Reddy's Strategic Vision Reiterated Following Strong Q1FY25 Results
Dr. Reddy's reported consolidated revenues of ₹7,673 crores (US$ 921 million) for Q1FY25, marking a 14% year-on-year increase and a 8% sequential growth.
Comparing Merck & Co With Industry Competitors In Pharmaceuticals Industry
In today's rapidly changing and highly competitive business world, it is imperative for investors and industry observers to carefully assess companies before making investment choices. In this article...
Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #AurigenePharmaceutical--Dr. Reddy's Laboratories, Aurigene, and Kainomyx announce potential partnership for joint development of affordable anti-malarial dr...
In-Depth Analysis: Merck & Co Versus Competitors In Pharmaceuticals Industry
In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry com...
Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy
Dr. Reddy's Laboratories stock has surged 29%, fueled by legislative changes and strong business momentum, with $107/share intrinsic value. Read more here.
Dr. Reddy's Laboratories: India 'will be our number one market'
Erez Israeli of Dr. Reddy's Laboratories says the company is "absolutely planning to play" in the biologics space, and while the U.S. remains a key market for the company, India and other markets will...
Dr. Reddy's Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #CHMP--Dr. Reddy's receives positive CHMP opinion from European Medicines Agency for its proposed Rituximab biosimilar.
Dr. Reddy's Q1FY25 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2024.
Dr. Reddy's to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Acquisition--Dr. Reddy's to acquire Nicotinell and related portfolio in significant step towards building global consumer healthcare business.
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
HYDERABAD, India--(BUSINESS WIRE)-- #Aurigene--Aurigene inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India.
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #CEO--Dr. Reddy's Laboratories Ltd. today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America.
Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #Alvotech--Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Proli...
Dr. Reddy's Laboratories Limited (RDY) Q4 2024 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (NYSE:RDY) Q4 2024 Earnings Conference Call May 7, 2024 10:00 AM ET Company Participants Richa Periwal - Head of Investor Relations GV Prasad - Co-Chairman and Managi...
Dr. Reddy's Q4 & Full Year FY24 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024.
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Capsules--Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S. market.
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Avastin--Dr. Reddy's Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal
Coya Therapeutics has strengthened its strategic positioning with a licensing deal with Dr. Reddy's, providing significant financial derisking and expanding its pipeline. The company has proven its ab...
Dr. Reddy's Q3 & 9M FY24 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #9MFY24--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2023.
Dr Reddy's Laboratories Ltd (RDY) Q3 2024 Earnings Call Transcript
Dr Reddy's Laboratories Ltd (RDY) Q3 2024 Earnings Call Transcript
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women's Health and Dietary Supplements Portfolio of Brands
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #AmyrisInc--Dr. Reddy's announces the acquisition of MenoLabs®, a leading women's health and dietary supplements portfolio of brands.
Dr. Reddy's becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DJSIWorld--Dr. Reddy's has won back-to-back global recognitions for its commitment and progress on sustainability and Environment Social and Governance agen...